scale average bioequivalence for parallel design [RSABE / ABEL]

posted by Mahmoud  – Jordan, 2022-06-15 14:33 (171 d 16:56 ago) – Posting: # 23059
Views: 797

Dear All
In the following paper

Statistical methodology for highly variable compounds: A novel design approach for the Ofatumumab Phase 2 bioequivalence study

Used scale average bioequivalence for parallel design

Is this method accepted by FDA and EMA


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
 Admin contact
22,427 posts in 4,694 threads, 1,598 registered users;
19 visitors (0 registered, 19 guests [including 6 identified bots]).
Forum time: 06:29 CET (Europe/Vienna)

Operational hectic replaces
intellectual calms.    Alexander Huiskes

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz